Literature DB >> 9728423

Chemotherapy in advanced pancreatic adenocarcinoma.

C Kollmannsberger1, H D Peters, U Fink.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728423     DOI: 10.1016/s0305-7372(98)90079-2

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

1.  Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.

Authors:  Soukaina Réjiba; Christelle Bigand; Céline Parmentier; Amor Hajri
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

2.  A composite smeared finite element for mass transport in capillary systems and biological tissue.

Authors:  M Kojic; M Milosevic; V Simic; E J Koay; J B Fleming; S Nizzero; N Kojic; A Ziemys; M Ferrari
Journal:  Comput Methods Appl Mech Eng       Date:  2017-06-29       Impact factor: 6.756

3.  A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.

Authors:  Junan Li; Jiuxiang Zhu; W Scott Melvin; Tanios S Bekaii-Saab; Ching-Shih Chen; Peter Muscarella
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

4.  Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

Authors:  Andrei V Ougolkov; Vladimir N Bilim; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

5.  Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung.

Authors:  Tatyana Kalinina; Cenap Güngör; Sabrina Thieltges; Maren Möller-Krull; Eva Maria Murga Penas; Daniel Wicklein; Thomas Streichert; Udo Schumacher; Viacheslav Kalinin; Ronald Simon; Benjamin Otto; Judith Dierlamm; Heidi Schwarzenbach; Katharina E Effenberger; Maximilian Bockhorn; Jakob R Izbicki; Emre F Yekebas
Journal:  BMC Cancer       Date:  2010-06-16       Impact factor: 4.430

6.  Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.

Authors:  Armando Lucero-Acuña; Justin J Jeffery; Edward R Abril; Raymond B Nagle; Roberto Guzman; Mark D Pagel; Emmanuelle J Meuillet
Journal:  Int J Nanomedicine       Date:  2014-12-03

7.  Overexpression of COL11A1 by cancer-associated fibroblasts: clinical relevance of a stromal marker in pancreatic cancer.

Authors:  Carmen García-Pravia; José A Galván; Natalia Gutiérrez-Corral; Lorena Solar-García; Eva García-Pérez; Marcos García-Ocaña; Jokin Del Amo-Iribarren; Primitiva Menéndez-Rodríguez; Juan García-García; Juan R de Los Toyos; Laureano Simón-Buela; Luis Barneo
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.